The Investor
29 Jul 2026, 15:49
Biogen Stock Rises After Barclays Raises Price Target Despite Maintaining Equal-Weight Rating
Biogen (NASDAQ: BIIB) shares were up about 4.6% on Wednesday after Barclays raised its price target on the biotechnology company to **$200 from $185**, while maintaining its **Equal Weight** rating.
The higher target price reflects improved confidence in Biogen's valuation and business outlook, although Barclays stopped short of becoming more bullish on the stock. An Equal Weight rating generally indicates the analyst expects the shares to perform roughly in line with the broader market or industry peers.
The revised $200 price target represents an increase of approximately 8% from the previous target and suggests additional upside from recent trading levels. Investors appeared to welcome the more optimistic valuation, pushing the stock higher in early trading.
The target increase comes as Biogen continues to execute on its strategy of expanding beyond its traditional multiple sclerosis franchise, with growing contributions from rare disease and neuroscience therapies. Investors are also closely watching the commercial performance of the company's Alzheimer's portfolio and pipeline developments, which remain key drivers of long-term growth expectations.
While Barclays' decision to raise its price target signals increased confidence in Biogen's prospects, the unchanged Equal Weight rating suggests the firm believes much of the company's improving outlook is already reflected in the stock price.
Biogen (NASDAQ: BIIB) shares were up about 4.6% on Wednesday after Barclays raised its price target on the biotechnology company to **$200 from $185**, while maintaining its **Equal Weight** rating.
The higher target price reflects improved confidence in Biogen's valuation and business outlook, although Barclays stopped short of becoming more bullish on the stock. An Equal Weight rating generally indicates the analyst expects the shares to perform roughly in line with the broader market or industry peers.
The revised $200 price target represents an increase of approximately 8% from the previous target and suggests additional upside from recent trading levels. Investors appeared to welcome the more optimistic valuation, pushing the stock higher in early trading.
The target increase comes as Biogen continues to execute on its strategy of expanding beyond its traditional multiple sclerosis franchise, with growing contributions from rare disease and neuroscience therapies. Investors are also closely watching the commercial performance of the company's Alzheimer's portfolio and pipeline developments, which remain key drivers of long-term growth expectations.
While Barclays' decision to raise its price target signals increased confidence in Biogen's prospects, the unchanged Equal Weight rating suggests the firm believes much of the company's improving outlook is already reflected in the stock price.
